Mometasone furoate/formoterol reduces asthma deteriorations and improves lung function

E O Meltzer; P Kuna; H Nolte; A S Nayak; C Laforce; Vibeke Backer; P04073 Study Investigators

doi:10.1183/09031936.00020310

Mometasone furoate/formoterol reduces asthma deteriorations and improves lung function

E O Meltzer, P Kuna, H Nolte, A S Nayak, C Laforce, Vibeke Backer, P04073 Study Investigators

18 Citations (Scopus)

Abstract

This study evaluated the effect of mometasone furoate (MF)/formoterol (F) versus its monocomponents, each administered via metered-dose inhaler, on asthma deteriorations and lung function. This 26-week, multicentre, double-blind, placebo-controlled study included subjects aged ≥12 yrs with not well-controlled asthma on low-dose inhaled corticosteroids. After a 2-3-week open-label run-in (MF 100 μg b.i.d.), 746 subjects were randomised to receive placebo, F 10 μg, MF 100 μg or MF/F 100/10 μg b.i.d. Co-primary end-points were time to first asthma deterioration (MF/F versus F to assess effect of MF) and change in forced expiratory volume in 1 s (FEV(1)) area under the curve of serial spirometry measurements over the 12-h period following the morning dose (AUC(0-12h)) (baseline to week 12; MF/F versus MF to assess effect of F). The therapeutic effect of MF in the combination was demonstrated by a reduction in asthma deterioration incidence with MF/F versus F and a delayed time to first asthma deterioration (p

Original language	English
Journal	European Respiratory Journal
Volume	39
Issue number	2
Pages (from-to)	279-89
Number of pages	11
ISSN	0903-1936
DOIs	https://doi.org/10.1183/09031936.00020310
Publication status	Published - 1 Feb 2012

Access to Document

10.1183/09031936.00020310

Cite this

@article{cf164851dafb4f09a743cfaf5ae2065f,

title = "Mometasone furoate/formoterol reduces asthma deteriorations and improves lung function",

abstract = "This study evaluated the effect of mometasone furoate (MF)/formoterol (F) versus its monocomponents, each administered via metered-dose inhaler, on asthma deteriorations and lung function. This 26-week, multicentre, double-blind, placebo-controlled study included subjects aged ≥12 yrs with not well-controlled asthma on low-dose inhaled corticosteroids. After a 2-3-week open-label run-in (MF 100 μg b.i.d.), 746 subjects were randomised to receive placebo, F 10 μg, MF 100 μg or MF/F 100/10 μg b.i.d. Co-primary end-points were time to first asthma deterioration (MF/F versus F to assess effect of MF) and change in forced expiratory volume in 1 s (FEV(1)) area under the curve of serial spirometry measurements over the 12-h period following the morning dose (AUC(0-12h)) (baseline to week 12; MF/F versus MF to assess effect of F). The therapeutic effect of MF in the combination was demonstrated by a reduction in asthma deterioration incidence with MF/F versus F and a delayed time to first asthma deterioration (p",

author = "Meltzer, {E O} and P Kuna and H Nolte and Nayak, {A S} and C Laforce and Vibeke Backer and Vibeke Backer",

year = "2012",

month = feb,

day = "1",

doi = "10.1183/09031936.00020310",

language = "English",

volume = "39",

pages = "279--89",

journal = "Acta tuberculosea Scandinavica",

issn = "0904-1850",

publisher = "European Respiratory Society",

number = "2",

}

TY - JOUR

T1 - Mometasone furoate/formoterol reduces asthma deteriorations and improves lung function

AU - Meltzer, E O

AU - Kuna, P

AU - Nolte, H

AU - Nayak, A S

AU - Laforce, C

AU - Backer, Vibeke

AU - P04073 Study Investigators

PY - 2012/2/1

Y1 - 2012/2/1

N2 - This study evaluated the effect of mometasone furoate (MF)/formoterol (F) versus its monocomponents, each administered via metered-dose inhaler, on asthma deteriorations and lung function. This 26-week, multicentre, double-blind, placebo-controlled study included subjects aged ≥12 yrs with not well-controlled asthma on low-dose inhaled corticosteroids. After a 2-3-week open-label run-in (MF 100 μg b.i.d.), 746 subjects were randomised to receive placebo, F 10 μg, MF 100 μg or MF/F 100/10 μg b.i.d. Co-primary end-points were time to first asthma deterioration (MF/F versus F to assess effect of MF) and change in forced expiratory volume in 1 s (FEV(1)) area under the curve of serial spirometry measurements over the 12-h period following the morning dose (AUC(0-12h)) (baseline to week 12; MF/F versus MF to assess effect of F). The therapeutic effect of MF in the combination was demonstrated by a reduction in asthma deterioration incidence with MF/F versus F and a delayed time to first asthma deterioration (p

AB - This study evaluated the effect of mometasone furoate (MF)/formoterol (F) versus its monocomponents, each administered via metered-dose inhaler, on asthma deteriorations and lung function. This 26-week, multicentre, double-blind, placebo-controlled study included subjects aged ≥12 yrs with not well-controlled asthma on low-dose inhaled corticosteroids. After a 2-3-week open-label run-in (MF 100 μg b.i.d.), 746 subjects were randomised to receive placebo, F 10 μg, MF 100 μg or MF/F 100/10 μg b.i.d. Co-primary end-points were time to first asthma deterioration (MF/F versus F to assess effect of MF) and change in forced expiratory volume in 1 s (FEV(1)) area under the curve of serial spirometry measurements over the 12-h period following the morning dose (AUC(0-12h)) (baseline to week 12; MF/F versus MF to assess effect of F). The therapeutic effect of MF in the combination was demonstrated by a reduction in asthma deterioration incidence with MF/F versus F and a delayed time to first asthma deterioration (p

U2 - 10.1183/09031936.00020310

DO - 10.1183/09031936.00020310

M3 - Journal article

C2 - 21828036

SN - 0904-1850

VL - 39

SP - 279

EP - 289

JO - Acta tuberculosea Scandinavica

JF - Acta tuberculosea Scandinavica

IS - 2

ER -

Mometasone furoate/formoterol reduces asthma deteriorations and improves lung function

Abstract

Access to Document

Fingerprint

Cite this